|
- New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Preclinical and observational studies suggest that exercise may improve cancer outcomes However, definitive level 1 evidence is lacking In this phase 3, randomized trial conducted at 55 centers,
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and . . .
GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials, International Journal of
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Clinical outcomes and safety of 7-day versus 14-day antibiotic therapy for bloodstream infections in adults: A systematic review and meta-analysis with trial sequential analysis, Journal of
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
A total of 1721 patients (1680 adults and 41 adolescents) underwent randomization and received brensocatib or placebo The annualized rate of pulmonary exacerbations was 1 02 in the 10-mg
- Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
|
|
|